<ul><li>London-based AI drug discovery company BenevolentAI has completed its previously announced EUR 1.5 billion (USD 1.6 billion) special purpose acquisition company (SPAC) deal —reportedly the largest European SPAC transaction ever. It started trading its common shares on the Euronext Amsterdam Market under the ticker symbol “BAI” effective from April 25, 2022.</ul>
The combined entity, following the completion of the deal on April 22, 2022, raised gross proceeds of EUR 225 million (USD 242 million). It will be used to fuel its internal clinical pipeline of over 20 drug programs, to complete phase 1/2 clinical trials of two of its candidates by 2023, and further develop its AI drug discovery platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.